Literature DB >> 3921419

Plasma apolipoproteins AI, AII, B, CI, and E are glucosylated in hyperglycemic diabetic subjects.

L K Curtiss, J L Witztum.   

Abstract

Nonenzymatic posttranslational glucosylation of the free amine of lysine residues can occur in hyperglycemic diabetic subjects. Using monoclonal antibodies that specifically bind the reduced conjugate of glucose covalently bound to the epsilon amine of lysine, glucitollysine, plasma lipoprotein glucosylation was demonstrated by radioimmunoassays in all subjects tested. Lipoproteins isolated from the plasma of diabetic subjects in poor metabolic control contained up to 33-fold increases in glucitollysine residues/mg of isolated lipoprotein protein, and on an absolute basis contained between 36 and 383 nmol of glucitollysine in their total lipoprotein fraction compared with normals, who had a mean of 2.9 +/- 0.06 nmol. The majority of the glucosylated protein in the d less than 1.125 g/ml fraction was present in the triglyceride-rich lipoproteins of hyperglycemic subjects, whereas the majority of the glucosylated protein in the d less than 1.125 g/ml fraction of euglycemic subjects was present in the high-density lipoproteins (HDL). A number of immunochemical approaches were used to demonstrate that, in diabetic plasma, apo AI, apo AII, apo B, apo CI, apo E, and albumin were glucosylated. Detailed studies of the apoproteins of a d less than or equal to 1.019 g/ml lipoprotein fraction and of an HDL fraction isolated from a hyperglycemic diabetic subject indicated that glucitollysine-specific antibodies can be used to preparatively isolate proteins containing glucosylated amino acid residues so that the extent of glucosylation in specific proteins can be measured. The results indicate that some of the lysine residues of the apoproteins can be modified in hyperglycemic diabetic subjects by the covalent attachment of glucose. The possible significance of these observations is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3921419     DOI: 10.2337/diab.34.5.452

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  28 in total

1.  High glucose levels do not directly impair cellular binding of HDL3 or HDL-mediated efflux of cholesterol from human skin fibroblasts.

Authors:  P B Duell; E L Bierman
Journal:  Acta Diabetol       Date:  1991       Impact factor: 4.280

Review 2.  High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease.

Authors:  Meliana Riwanto; Ulf Landmesser
Journal:  J Lipid Res       Date:  2013-07-20       Impact factor: 5.922

Review 3.  Derangements of intravascular remodeling of lipoproteins in type 2 diabetes mellitus: consequences for atherosclerosis development.

Authors:  Geesje M Dallinga-Thie; Robin P F Dullaart; Arie van Tol
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

4.  The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase.

Authors:  E Nobecourt; M J Davies; B E Brown; L K Curtiss; D J Bonnet; F Charlton; A S Januszewski; A J Jenkins; P J Barter; K-A Rye
Journal:  Diabetologia       Date:  2007-01-10       Impact factor: 10.122

Review 5.  Novel biological functions of high-density lipoprotein cholesterol.

Authors:  Chieko Mineo; Philip W Shaul
Journal:  Circ Res       Date:  2012-09-28       Impact factor: 17.367

Review 6.  Biomarkers associated with high-density lipoproteins in atherosclerotic kidney disease.

Authors:  Kerry-Anne Rye
Journal:  Clin Exp Nephrol       Date:  2013-09-20       Impact factor: 2.801

Review 7.  HDL dysfunction in diabetes: causes and possible treatments.

Authors:  Dan Farbstein; Andrew P Levy
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-03

8.  Type I diabetes mellitus decreases in vivo macrophage-to-feces reverse cholesterol transport despite increased biliary sterol secretion in mice.

Authors:  Jan Freark de Boer; Wijtske Annema; Marijke Schreurs; Jelske N van der Veen; Markus van der Giet; Niels Nijstad; Folkert Kuipers; Uwe J F Tietge
Journal:  J Lipid Res       Date:  2011-12-18       Impact factor: 5.922

9.  Metabolism by human endothelial cells of very low density lipoprotein subfractions isolated from type 1 (insulin-dependent) diabetic patients.

Authors:  R L Klein; M F Lopes-Virella
Journal:  Diabetologia       Date:  1993-03       Impact factor: 10.122

10.  Inhibiting low-density lipoprotein glycation ameliorates increased cholesteryl ester synthesis in macrophages and hypercholesterolemia and aortic lipid peroxidation in streptozotocin diabetic rats.

Authors:  Margo P Cohen; Elizabeth A Shea; Van-Yu Wu
Journal:  Metabolism       Date:  2009-11-18       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.